NEW YORK, March 11, 2025–(BUSINESS WIRE)–OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies…
Continue ReadingNEW YORK, March 11, 2025–(BUSINESS WIRE)–OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies…
Continue Reading